You are here

Share:

Peptide Inhibitor for Treating Inflammatory Autoimmune Diseases and Inflammatory Cancers

Summary
The National Cancer Institute’s Laboratory of Immune Cell Biology seeks partners interested in licensing or collaborative research to co-develop peptide-based therapeutics for inflammatory autoimmune conditions or inflammatory cancers.
NIH Reference Number
E-281-2012
Product Type
Keywords
  • Inflammation
  • autoimmune
  • inflammatory cancers
  • p38 map kinase
  • Gadd45a
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Growth arrest and DNA-damage-inducible protein GADD45 alpha (Gadd45a) is a protein involved in the p38 MAP kinase signaling pathway.  Inventors at the NCI have developed a 15 amino acid peptide fragment of Gadd45a that retains the functionality of Gadd45a by inhibiting enzymatic activity of tyrosine-323-phosphorylaled p38 in vitro.  The peptide is modified to make it cell permeable and exhibits minimal toxicity in vitro.  The fragment readily penetrates T cells to inhibit (a) proliferation in response to T cell receptor-mediated stimulation; (b) skewing of T cells to Th I and Th 17 cells; and (c) inflammatory cytokine production.  As a result, this fragment has anti-inflammatory properties and has potential as a therapeutic for inflammatory autoimmune conditions or inflammatory cancers, such as pancreatic cancer.

Potential Commercial Applications
  • Treatment for inflammatory autoimmune conditions or inflammatory cancers, such as pancreatic cancer.
Competitive Advantages
  • Minimal cellular toxicity
Development Stage
Patent Status
  • U.S. Patent Issued: U.S. Patent Number 9359418
Therapeutic Area
Updated
Tuesday, September 6, 2016